shutterstock_1621552165_shawnwil23

shutterstock_1621552165_shawnwil23

30 June 2022Big Pharma

English High Court rejects second injunction bid over melatonin medicine

Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Mylan gets green light to challenge Neurim melatonin patent

25 January 2022 Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Neurim, Flynn discover that time is not on their side

26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

More on this story

Mylan gets green light to challenge Neurim melatonin patent

25 January 2022 Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Neurim, Flynn discover that time is not on their side

26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

More on this story

Mylan gets green light to challenge Neurim melatonin patent

25 January 2022 Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Neurim, Flynn discover that time is not on their side

26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers